Lite Strategy: From Biotech To Litecoin Treasury

Company Overview - Lite Strategy Inc. (NASDAQ: LITS), previously known as MEI Pharma, Inc. and traded under the ticker "MEIP," was focused on oncology with two drug candidates, vorucliclib and ME-144, which were intended for use in oncology combination therapies [1]. Analyst Background - The article includes a brief background of Myriam Hernandez Alvarez, who holds multiple degrees in engineering, computer science, business management, and computer applications, indicating a strong academic foundation relevant to the analysis presented [1]. Disclosure Information - The article contains disclosures regarding the author's lack of stock or derivative positions in the companies mentioned, emphasizing an independent analysis without financial incentives [2].